Introduction {#Sec1}
============

[d]{.smallcaps}-Amino acids, long-term undetected enantiomers of [l]{.smallcaps}-amino acids \[[@CR1]--[@CR3]\], are now emerging as potential biomarkers for several diseases including kidney diseases \[[@CR4], [@CR5]\]. In spite of their trace amount, [d]{.smallcaps}-serine does exist in human body \[[@CR4]\], and plasma [d]{.smallcaps}-serine is now standing out with its usefulness in the estimation of kidney function, glomerular filtration ratio (GFR) \[[@CR5]\], and in the prediction of the prognoses of the patients with chronic kidney disease (CKD) \[[@CR4]\]. Additionally, urinary fractional excretion (FE) of [d]{.smallcaps}-serine turned out to have an association with the presence of kidney diseases \[[@CR5]\]. These features of [d]{.smallcaps}-serine would potentiate the comprehensive management of CKD.

In light of clinical application, the question if the intra-body dynamics of [d]{.smallcaps}-serine reflect the disease course of kidney diseases arises. For example, do the profiles of [d]{.smallcaps}-serine reflect worsening or recovery phase of kidney injury? Based on the fact that the profiles of [d]{.smallcaps}-serine well correlate with GFR and are associated with the presence of kidney diseases, the profiles of [d]{.smallcaps}-serine may sensitively respond to the treatment of kidney diseases. If this is the case, [d]{.smallcaps}-serine can be utilized as biomarkers that can also reflect the effects of therapy.

We experienced a case of systemic lupus erythematosus (SLE), who had undergone a severe course of rapid progressive glomerular nephritis that responded well to the intensive care. We report the informative profile of [d]{.smallcaps}-serine of this case.

Concise description of this case {#Sec2}
--------------------------------

Full clinical course of this case is described in the supplemental file. In brief, this case is a 36-year-old woman presented with RPGN. Laboratory test at kidney biopsy showed acute worsening of serum creatinine to 1032 μmol/L, high level of urinary protein (4 g/gCre), strong anemia (blood hemoglobin, 4.6 g/dL), normal levels of complements (C3, 88 mg/dL; C4, 21 mg/dL), positive anti-DNA antibody (13.0 IU/mL), and positive P-ANCA (182.0 U/mL). Kidney biopsy identified crescentic glomerulonephritis, potentially associated with ANCA, and SLE nephritis class V.

A series of plasma exchange was initiated followed by prednisolone pulse, oral prednisolone, intravenous cyclophosphamide, and mycophenolate mofetil. In response to these therapies, serum creatinine level improved to 63.65 μmol/L, while urinary protein level persisted. Followed-up kidney biopsy showed regression of cellular crescents in glomeruli, while 30% of glomeruli were globally sclerosed and capillary thickenings persisted.

Dynamics of [d]{.smallcaps}-amino acids in this patient during the recovery phase {#Sec3}
---------------------------------------------------------------------------------

We examined the levels of [d]{.smallcaps}-amino acids throughout the recovery phase of RPGN due to SLE nephritis in this patient. Blood levels of [d]{.smallcaps}-amino acids at acute phase (just after admission to the hospital) were extraordinary; blood level of [d]{.smallcaps}-serine was extremely high and comprised 19% of whole blood serine (ranges of non-CKD were 1.22--1.85%, Fig. [1](#Fig1){ref-type="fig"} and Supplementary Tables S1 and S2). [d]{.smallcaps}-Alanine and [d]{.smallcaps}-proline, which are often detected in normal population, were also high in this patient; these [d]{.smallcaps}-amino acids comprised 2.2% and 3.1% of each amino acid, respectively.Fig. 1Plasma [d]{.smallcaps}-amino acids per total amino acids (*D* ratio \[%\]) of this patient on admission. Reference data (non-CKD and CKD) are from \[[@CR5]\]. *CKD* chronic kidney disease

Among [d]{.smallcaps}-amino acids, [d]{.smallcaps}-serine was demonstrated to reflect GFR \[[@CR5]\]. In this patient, blood levels of [d]{.smallcaps}-serine decreased in response to the treatment and these decreases were in parallel with those of blood creatinine levels. Finally, blood levels of [d]{.smallcaps}-serine further decreased to the normal ranges.

Since FE of [d]{.smallcaps}-amino acids was reported to reflect disease profile in CKD \[[@CR5]\], we also examined FE of [d]{.smallcaps}-amino acids during the clinical course of this patient (Fig. [2](#Fig2){ref-type="fig"}a, b). FE of [d]{.smallcaps}-serine was calculated as follows: urinary [d]{.smallcaps}-serine times blood creatinine divided by urinary creatinine and blood [d]{.smallcaps}-serine. FE is the ratio of a substrate filtered by the kidney glomerular that is excreted in the urine. At the initial course of this case, FE of [d]{.smallcaps}-serine was 0% due to no excretion of [d]{.smallcaps}-serine into the urine. FE of [d]{.smallcaps}-serine usually is reported to take wide ranges similarly in both normal and CKD population, whereas 0% of FE of [d]{.smallcaps}-serine was completely out of those ranges. FE of [d]{.smallcaps}-serine remained 0% until the end of plasma exchange sessions. During the recovery phase, FE of [d]{.smallcaps}-serine increased transiently even though the blood levels of both creatinine and [d]{.smallcaps}-serine were still high, reflecting the increased excretion of [d]{.smallcaps}-serine at this stage. After the series of treatment described here, blood level and FE of [d]{.smallcaps}-serine finally normalized to the profile compatible with normal population.Fig. 2Dynamics of [d]{.smallcaps}-serine during the recovery phase of this patient. **a** Clinical course of this patient. *PSL* prednisolone, *IVCY* intravenous cyclophosphamide, *MMF* mycophenolate mofetil. **b** Dynamics of [d]{.smallcaps}-serine were plotted on a scatter plot with reference data \[[@CR5]\]. The eclipse represents 95% confidence interval of non-CKD population. Each numbered dot of this patient reflected the following clinical course: 1, day 1 (on admission); 2, day 9 (before the first plasma exchange); 3, day 13 (before the second plasma exchange); 4, day 30 (after 8 sessions of plasma exchange); 5, day 35 (after IVCY); 6, day 49 (after the initial treatment just before the discharge)

Discussion {#Sec4}
==========

We experienced a case of RPGN with dynamic changes in both blood level and FE of [d]{.smallcaps}-serine during the recovery phase. At the fulminant phase of RPGN, the blood levels of [d]{.smallcaps}-serine were extremely high. On the other hand, FE of [d]{.smallcaps}-serine, which was usually much higher than that of [l]{.smallcaps}-isoform, was 0% in this patient. These abnormal [d]{.smallcaps}-serine profiles normalized in response to the intensive treatment. Normalizations of the blood levels of [d]{.smallcaps}-serine were in parallel with those of creatinine. During the recovery phase, FE of [d]{.smallcaps}-serine increased transiently and exceeded the normal ranges, followed by a drop in the normal ranges. This dynamic [d]{.smallcaps}-serine profile well reflected the clinical course of this patient.

Plasma [d]{.smallcaps}-serine may serve as a sensitive marker for AKI and RPGN. Our previous study revealed that [d]{.smallcaps}-serine reflects kidney function, GFR, and the presence of CKD \[[@CR5]\]. [d]{.smallcaps}-Amino acids were known to be handled by kidney; after glomerular filtration, kidney reabsorbs amino acids at proximal tubules with chiral selectivity. In CKD patients with decreased GFR, blood levels of [d]{.smallcaps}-serine increased due to less glomerular filtration of [d]{.smallcaps}-serine. In line with this study, plasma level of [d]{.smallcaps}-serine also reflected recovery phase of RPGN. The abnormally high blood level of [d]{.smallcaps}-serine resolved with the treatment of SLE, and the longitudinal course of plasma level of [d]{.smallcaps}-serine was in parallel with serum level of creatinine, reflecting the recovery of GFR. Plasma [d]{.smallcaps}-serine may be applicable in examining treatment effects in AKI. Additionally, plasma [d]{.smallcaps}-serine may also be useful in detecting AKI and RPGN. The presence of a time lag between GFR decrease and blood creatinine increase in AKI is widely known, and whether blood [d]{.smallcaps}-serine responds to AKI promptly or not needs to be examined. Once nephrologists all over the world noticed the value of [d]{.smallcaps}-serine and started using it, we believe the cost will be reduced very rapidly, and [d]{.smallcaps}-serine will be available for daily clinics soon.

On the other hand, the reabsorption of [d]{.smallcaps}-serine is sensitive to the presence of CKD \[[@CR5]\]. FE of [d]{.smallcaps}-serine increases in some patients with normal ranges of blood [d]{.smallcaps}-serine level, suggesting that the increment of FE of [d]{.smallcaps}-serine is a compensatory mechanism to keep blood [d]{.smallcaps}-serine levels low. Another patient showed decreased FE of [d]{.smallcaps}-serine, possibly due to decreased GFR, which in turn increased the blood [d]{.smallcaps}-serine levels. Therefore, FE of [d]{.smallcaps}-serine proceeded the increase of plasma [d]{.smallcaps}-serine and turned out as a useful marker for detecting kidney diseases before the worsening of GFR.

This concept was exemplified in this patient; the kidney promotes urinary excretion of [d]{.smallcaps}-serine for the normalization of plasma [d]{.smallcaps}-serine level. Increase in FE of [d]{.smallcaps}-serine during the recovery phase may represent the efficacy of the treatment, a feature essential for the drug discovery in kidney diseases.

In summary, we experienced a case of RPGN due to SLE nephritis accompanied with dynamic profiles of [d]{.smallcaps}-serine during its recovery phase. Blood levels of both creatinine and [d]{.smallcaps}-serine normalized in response to the treatment, and transient increase in urinary FE of [d]{.smallcaps}-serine played a role in normalization. Blood [d]{.smallcaps}-serine can serve as a biomarker for AKI and RPGN by reflecting GFR. Those lines of thus-far unexplored course of [d]{.smallcaps}-serine suggest the robust utility as a biomarker to monitor disease activity of kidney diseases and the treatment effects.
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